Immunological Reactivity in Patients with Systemic Lupus Erythematosus: Humoral Antibody and Cellular Immune Responses

Abe, Tohru; Homma, Mitsuo

doi:10.3109/rhe1.1971.17.issue-1-4.06

Cited by 64 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kiray et al 65 found reduced induration sizes in the tuberculin skin test in 115 patients with JIA on low-dose immunosuppressive drugs. Abe et al 66 found similar results in their study, where 20 patients with SLE were evaluated. Freire et al 67 have reported that four patients with jSLE on immunsupressive drugs presented miliary tuberculosis.…”

Section: Bacillus Calmette-guérin Vaccinesupporting

confidence: 73%

Current information about vaccination practice in pediatric rheumatic diseases and recommendations for future applications

Açarı

Ünsal

2017

Turk J Pediatr

View full text Add to dashboard Cite

Section: Bacillus Calmette-guérin Vaccinesupporting

confidence: 73%

Current information about vaccination practice in pediatric rheumatic diseases and recommendations for future applications

Açarı

Ünsal

2017

Turk J Pediatr

View full text Add to dashboard Cite

“…Corticosteroid therapy may contribute t o depressed phagocytosis and infection in SLE, but infections were a frequent cause of death in the precorticosteroid era (32) and SLE patients on no or low doses of steroids are prone to develop infection in comparison t o similarly treated patients with rheumatoid arthritis and nephrotic syndrome (33). Whatever the mechanism whereby serum from patients with SLE suppresses phagocytosis and release of lysosomal enzymes, it may help explain other defects in cell-mediated immunity that have been demonstrated in SLE patients (7)(8)(9). Isolation and characterization of the suppressor factor(s) a n d more precise definitions of its mode of action are necessary.…”

Section: Discussionmentioning

confidence: 99%

Reduction of phagocytosis and lysosomal enzyme release from human leukocytes by serum from patients with systemic lupus erythematosus

Zurier

1976

Arthritis & Rheumatism

View full text Add to dashboard Cite

Serums from 22 of 30 (73.3%) patients with systemic lupus erythematosus (SLE) interfered significantly with particle (zymosan) uptake and subsequent release from normal human neutrophils of lysosomal enzymes. SLE serums with low as well as those with normal functional hemolytic complement activity (CH50) suppressed phagocytosis and enzyme release despite the presence of normal serum in cell suspensions. The defect did not appear to be caused by anticomplementary activity of serum. Serums from patients whose clinical activity of disease varied from none to severe and whose treatment varied from none to high doses of prednisone were capable of suppressing phagocytosis and enzyme release. The severity of clinical SLE activity did not affect the degree of suppression. Serums from patients treated with corticosteroids were more inhibitory than serums from patients not so treated. The nature of the inhibitor is unknown.Phagocytic cells become the center of inflammatory lesions (1) partly because of release of substances previously sequestered within lysosomes. During uptake of particles such as zymosan and immune com-

show abstract

“…Greatly reduced numbers of T inducerhelper cells in SLE would explain, at least in part, the broad defects in cell-mediated immunity characteristic of this disorder (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12).…”

Section: Discussionmentioning

confidence: 99%

T Lymphocyte Subsets in Systemic Lupus Erythematosus

Bakke

Kirkland

Kitridou

et al. 1983

Arthritis & Rheumatism

View full text Add to dashboard Cite

The contribution of immune regulation to the etiology of systemic lupus erythematosus (SLE) is poorly understood. Using the monoclonal antibodies OKT4 and OKTS, we quantitated, by flow cytometry, T inducer/ helper and T cytotoxicfsuppressor cells in patients with SLE. Serologically active patients, who had clinical manifestations such as arthritis or rash and were not receiving prednisone, were characteristically lymphopenic due to a marked reduction in OKT4+ cells. Prednisone therapy produced the same phenomenon. Untreated patients, who were serologically inactive, demonstrated no abnormalities. These studies have thus revealed two presumably independent factors that can produce similar immunoregulatory aberrations.Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by excessive immunoglobulin and autoantibody production. Although B cell function is increased, T cell functions which include delayed hypersensitivity (1-3, mitogenic reactivity (6,7), generation of antigen-specific reactivities (8), and development of nonspecific suppressor (14).We studied 28 patients with SLE who were divided into groups based on corticosteroid therapy and serologic evidence of disease activity. We will describe clinically significant abnormalities in the absolute number and relative proportions of immunoregulatory T cell subsets based upon this classification. PATIENTS AND METHODSPatients. This study included 28 patients (24 females, 4 males) with SLE according to the American Rheumatism Association ( M A ) preliminary criteria (15). Two to 3 patients were randomly selected in the lupus clinic visits each month from April 1981 to April 1982. These patients were then separated into 2 groups based on existing therapy, one receiving more than 10 mg prednisone per day, the other receiving 10 mg or less of prednisone per day. A special attempt was made to isolate newly diagnosed lupus patients being treated with 10 mg or less prednisone per day. During this 1-year period, 11 newly diagnosed patients were seen, but only 6 had 4 or more ARA preliminary criteria; of these 6, only 5 were treated with less than 10 mg prednisone per day.Control groups consisted of 16 women and 5 men with scleroderma and 16 patients with lepromatous leprosy. They will be described in detail elsewhere. Normal individ-

show abstract

Immunological Reactivity in Patients with Systemic Lupus Erythematosus: Humoral Antibody and Cellular Immune Responses

Cited by 64 publications

References 29 publications

Current information about vaccination practice in pediatric rheumatic diseases and recommendations for future applications

Current information about vaccination practice in pediatric rheumatic diseases and recommendations for future applications

Reduction of phagocytosis and lysosomal enzyme release from human leukocytes by serum from patients with systemic lupus erythematosus

T Lymphocyte Subsets in Systemic Lupus Erythematosus

Contact Info

Product

Resources

About